JP2015517470A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517470A5
JP2015517470A5 JP2015510508A JP2015510508A JP2015517470A5 JP 2015517470 A5 JP2015517470 A5 JP 2015517470A5 JP 2015510508 A JP2015510508 A JP 2015510508A JP 2015510508 A JP2015510508 A JP 2015510508A JP 2015517470 A5 JP2015517470 A5 JP 2015517470A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
seq
acid sequence
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015510508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517470A (ja
JP6411329B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/039744 external-priority patent/WO2013166500A1/en
Publication of JP2015517470A publication Critical patent/JP2015517470A/ja
Publication of JP2015517470A5 publication Critical patent/JP2015517470A5/ja
Application granted granted Critical
Publication of JP6411329B2 publication Critical patent/JP6411329B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015510508A 2012-05-04 2013-05-06 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 Active JP6411329B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261642749P 2012-05-04 2012-05-04
US61/642,749 2012-05-04
US201361785559P 2013-03-14 2013-03-14
US61/785,559 2013-03-14
PCT/US2013/039744 WO2013166500A1 (en) 2012-05-04 2013-05-06 Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018120054A Division JP6704954B2 (ja) 2012-05-04 2018-06-25 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法

Publications (3)

Publication Number Publication Date
JP2015517470A JP2015517470A (ja) 2015-06-22
JP2015517470A5 true JP2015517470A5 (enExample) 2016-06-23
JP6411329B2 JP6411329B2 (ja) 2018-10-24

Family

ID=48428719

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015510508A Active JP6411329B2 (ja) 2012-05-04 2013-05-06 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法
JP2018120054A Active JP6704954B2 (ja) 2012-05-04 2018-06-25 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法
JP2020084311A Pending JP2020127426A (ja) 2012-05-04 2020-05-13 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法
JP2022086515A Withdrawn JP2022119907A (ja) 2012-05-04 2022-05-27 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018120054A Active JP6704954B2 (ja) 2012-05-04 2018-06-25 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法
JP2020084311A Pending JP2020127426A (ja) 2012-05-04 2020-05-13 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法
JP2022086515A Withdrawn JP2022119907A (ja) 2012-05-04 2022-05-27 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法

Country Status (7)

Country Link
US (4) US9441045B2 (enExample)
EP (2) EP3511343A1 (enExample)
JP (4) JP6411329B2 (enExample)
AU (1) AU2013256010B2 (enExample)
CA (1) CA2871751C (enExample)
HK (1) HK1207655A1 (enExample)
WO (1) WO2013166500A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2585004B2 (ja) 1987-07-15 1997-02-26 太洋鋳機株式会社 連続式混練機における自動清掃装置
WO2013166500A1 (en) * 2012-05-04 2013-11-07 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
EP3054975A4 (en) * 2013-10-11 2017-06-28 Sloan-Kettering Institute for Cancer Research Methods and compositions for regulatory t-cell ablation
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
AU2015328273B2 (en) 2014-10-06 2020-09-17 Dana-Farber Cancer Institute, Inc. Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
KR102923234B1 (ko) 2014-12-19 2026-02-04 다나-파버 캔서 인스티튜트 인크. 키메라 항원 수용체 및 이의 사용 방법
NZ736863A (en) * 2015-05-01 2024-04-26 Dana Farber Cancer Inst Inc Methods of mediating cytokine expression with anti ccr4 antibodies
HUE063377T2 (hu) 2015-12-22 2024-01-28 Regeneron Pharma Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére
TWI786044B (zh) 2016-05-13 2022-12-11 美商再生元醫藥公司 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
WO2018057585A1 (en) * 2016-09-21 2018-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
CN110214152B (zh) 2016-10-14 2025-06-13 丹娜法伯癌症研究所公司 模块化四聚体双特异性抗体平台
KR20240011262A (ko) 2017-02-21 2024-01-25 리제너론 파아마슈티컬스, 인크. 폐암의 치료를 위한 항-pd-1 항체
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
RU2020118594A (ru) 2017-11-06 2021-12-09 Рапт Терапьютикс, Инк. Противораковые агенты
CN108250290B (zh) 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 Ccr4的n端重组蛋白及其用途
WO2019178356A1 (en) 2018-03-14 2019-09-19 Dana-Farber Cancer Institute, Inc. Engineered cells, t cell immune modulating antibodies and methods for using the same
CA3105985A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
AU2019387566A1 (en) 2018-11-30 2021-06-17 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof
WO2020252472A2 (en) 2019-06-14 2020-12-17 Dana-Farber Cancer Institute, Inc. Antibodies against muc1 and methods of use thereof
CN113388640B (zh) * 2020-06-11 2022-12-20 百奥赛图(北京)医药科技股份有限公司 Ccr4基因人源化的非人动物及其构建方法和应用
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
AU2022251320A1 (en) * 2021-04-01 2023-10-19 4C Biomed Limited Enhanced anti-hvem antibodies and use thereof
WO2024163530A2 (en) * 2023-02-01 2024-08-08 Crown Bioscience Inc. Novel anti-ccr4 antibodies and derivative products
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
AU681997B2 (en) 1991-09-05 1997-09-18 University Of Connecticut, The Targeted delivery of poly- or oligonucleotides to cells
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US8962806B2 (en) * 2007-12-28 2015-02-24 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
GB0909906D0 (en) * 2009-06-09 2009-07-22 Affitech As Antibodies
WO2013166500A1 (en) * 2012-05-04 2013-11-07 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device

Similar Documents

Publication Publication Date Title
JP2020127426A5 (enExample)
Goebeler et al. Bispecific and multispecific antibodies in oncology: opportunities and challenges
JP2015535691A5 (enExample)
JP2022159548A5 (enExample)
JP2020193210A5 (enExample)
JP2017531427A5 (enExample)
CN110291109B (zh) 人程序性死亡受体pd-1的单克隆抗体及其片段
JP2013502913A5 (enExample)
ES2887299T3 (es) Cadena J modificada
JP2019513777A5 (enExample)
JP2013227339A5 (enExample)
JP2020103301A5 (enExample)
JP2017537972A5 (enExample)
JP2020525032A5 (enExample)
JP2017506067A5 (enExample)
JP2021508255A5 (enExample)
JP2014076062A5 (enExample)
JP2019536430A5 (enExample)
US20240199750A1 (en) Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
JP2015502138A5 (enExample)
JP2018502060A5 (enExample)
JP2020515247A5 (enExample)
JP2021512151A5 (enExample)
JP2021510736A5 (enExample)
JP2016513467A5 (enExample)